FDA-like AI safety approval process delays NVIDIA's next-gen GPU by Q4 2026

If the Trump administration implements an FDA-like approval process for advanced AI models, NVIDIA's next-generation GPUs—expected to power cutting-edge AI systems—will face mandatory safety reviews. This could delay commercial releases by at least one quarter.

Implied probability (Yes)

60%